{"pmid":32173256,"title":"SARS Coronavirus Redux.","text":["SARS Coronavirus Redux.","As an atypical pneumonia began to appear in December 2019, Zhou et al. worked with remarkable speed to identify the associated virus, determine its relationship to animal viruses, and evaluate factors conferring infection susceptibility and resistance. These foundational results are being advanced to control the current worldwide human coronavirus epidemic.","Trends Immunol","Qing, Enya","Gallagher, Tom","32173256"],"abstract":["As an atypical pneumonia began to appear in December 2019, Zhou et al. worked with remarkable speed to identify the associated virus, determine its relationship to animal viruses, and evaluate factors conferring infection susceptibility and resistance. These foundational results are being advanced to control the current worldwide human coronavirus epidemic."],"journal":"Trends Immunol","authors":["Qing, Enya","Gallagher, Tom"],"date":"2020-03-17T11:00:00Z","year":2020,"_id":"32173256","week":"202012|Mar 16 - Mar 22","doi":"10.1016/j.it.2020.02.007","source":"PubMed","topics":["Mechanism"],"weight":1,"_version_":1661456248855330816,"score":6.7365713,"similar":[{"pmid":32057211,"title":"[An update on the epidemiological characteristics of novel coronavirus pneumoniaCOVID-19].","text":["[An update on the epidemiological characteristics of novel coronavirus pneumoniaCOVID-19].","Through literature review and group discussion, Special Expert Group for Control of the Epidemic of Novel Coronavirus Pneumonia of the Chinese Preventive Medicine Association formulated an update on the epidemiological characteristics of novel coronavirus pneumonia (NCP). The initial source of the 2019 novel coronavirus (2019-nCoV) was the Huanan seafood market in Wuhan, Hubei province, China, with pangolins as a potential animal host. Currently the main source of infection is NCP patients, and asymptomatic carriers may also be infectious. The virus is believed transmitted mostly via droplets or contact. People are all generally susceptible to the virus. The average incubation period was 5.2 days, and the basic reproductive number R(0) was 2.2 at the onset of the outbreak. Most NCP patients were clinically mild cases. The case fatality rate was 2.38%, and elderly men with underlying diseases were at a higher risk of death. Strategies for prevention and control of NCP include improving epidemic surveillance, quarantining the source of infection, speeding up the diagnosis of suspected cases, optimizing the management of close contacts, tightening prevention and control of cluster outbreaks and hospital infection, preventing possible rebound of the epidemic after people return to work from the Chinese Spring Festival holiday, and strengthening community prevention and control.","Zhonghua Liu Xing Bing Xue Za Zhi","32057211"],"abstract":["Through literature review and group discussion, Special Expert Group for Control of the Epidemic of Novel Coronavirus Pneumonia of the Chinese Preventive Medicine Association formulated an update on the epidemiological characteristics of novel coronavirus pneumonia (NCP). The initial source of the 2019 novel coronavirus (2019-nCoV) was the Huanan seafood market in Wuhan, Hubei province, China, with pangolins as a potential animal host. Currently the main source of infection is NCP patients, and asymptomatic carriers may also be infectious. The virus is believed transmitted mostly via droplets or contact. People are all generally susceptible to the virus. The average incubation period was 5.2 days, and the basic reproductive number R(0) was 2.2 at the onset of the outbreak. Most NCP patients were clinically mild cases. The case fatality rate was 2.38%, and elderly men with underlying diseases were at a higher risk of death. Strategies for prevention and control of NCP include improving epidemic surveillance, quarantining the source of infection, speeding up the diagnosis of suspected cases, optimizing the management of close contacts, tightening prevention and control of cluster outbreaks and hospital infection, preventing possible rebound of the epidemic after people return to work from the Chinese Spring Festival holiday, and strengthening community prevention and control."],"journal":"Zhonghua Liu Xing Bing Xue Za Zhi","date":"2020-02-15T11:00:00Z","year":2020,"_id":"32057211","week":"20207|Feb 10 - Feb 16","doi":"10.3760/cma.j.issn.0254-6450.2020.02.002","keywords":["Characteristics","Corona virus disease 2019(COVID-19)","Epidemiology","Novel coronavirus pneumonia"],"source":"PubMed","locations":["Huanan","Wuhan","Hubei","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism"],"weight":1,"_version_":1661359647272992768,"score":75.29203},{"pmid":32088679,"title":"2019-nCoV (Wuhan virus), a novel Coronavirus: human-to-human transmission, travel-related cases, and vaccine readiness.","text":["2019-nCoV (Wuhan virus), a novel Coronavirus: human-to-human transmission, travel-related cases, and vaccine readiness.","On 31 December 2019 the Wuhan Health Commission reported a cluster of atypical pneumonia cases that was linked to a wet market in the city of Wuhan, China. The first patients began experiencing symptoms of illness in mid-December 2019. Clinical isolates were found to contain a novel coronavirus with similarity to bat coronaviruses. As of 28 January 2020, there are in excess of 4,500 laboratory-confirmed cases, with > 100 known deaths. As with the SARS-CoV, infections in children appear to be rare. Travel-related cases have been confirmed in multiple countries and regions outside mainland China including Germany, France, Thailand, Japan, South Korea, Vietnam, Canada, and the United States, as well as Hong Kong and Taiwan. Domestically in China, the virus has also been noted in several cities and provinces with cases in all but one provinence. While zoonotic transmission appears to be the original source of infections, the most alarming development is that human-to-human transmission is now prevelant. Of particular concern is that many healthcare workers have been infected in the current epidemic. There are several critical clinical questions that need to be resolved, including how efficient is human-to-human transmission? What is the animal reservoir? Is there an intermediate animal reservoir? Do the vaccines generated to the SARS-CoV or MERS-CoV or their proteins offer protection against 2019-nCoV? We offer a research perspective on the next steps for the generation of vaccines. We also present data on the use of in silico docking in gaining insight into 2019-nCoV Spike-receptor binding to aid in therapeutic development. Diagnostic PCR protocols can be found at https://www.who.int/health-topics/coronavirus/laboratory-diagnostics-for-novel-co ronavirus.","J Infect Dev Ctries","Ralph, Robyn","Lew, Jocelyne","Zeng, Tiansheng","Francis, Magie","Xue, Bei","Roux, Melissa","Toloue Ostadgavahi, Ali","Rubino, Salvatore","Dawe, Nicholas J","Al-Ahdal, Mohammed N","Kelvin, David J","Richardson, Christopher D","Kindrachuk, Jason","Falzarano, Darryl","Kelvin, Alyson Anne","32088679"],"abstract":["On 31 December 2019 the Wuhan Health Commission reported a cluster of atypical pneumonia cases that was linked to a wet market in the city of Wuhan, China. The first patients began experiencing symptoms of illness in mid-December 2019. Clinical isolates were found to contain a novel coronavirus with similarity to bat coronaviruses. As of 28 January 2020, there are in excess of 4,500 laboratory-confirmed cases, with > 100 known deaths. As with the SARS-CoV, infections in children appear to be rare. Travel-related cases have been confirmed in multiple countries and regions outside mainland China including Germany, France, Thailand, Japan, South Korea, Vietnam, Canada, and the United States, as well as Hong Kong and Taiwan. Domestically in China, the virus has also been noted in several cities and provinces with cases in all but one provinence. While zoonotic transmission appears to be the original source of infections, the most alarming development is that human-to-human transmission is now prevelant. Of particular concern is that many healthcare workers have been infected in the current epidemic. There are several critical clinical questions that need to be resolved, including how efficient is human-to-human transmission? What is the animal reservoir? Is there an intermediate animal reservoir? Do the vaccines generated to the SARS-CoV or MERS-CoV or their proteins offer protection against 2019-nCoV? We offer a research perspective on the next steps for the generation of vaccines. We also present data on the use of in silico docking in gaining insight into 2019-nCoV Spike-receptor binding to aid in therapeutic development. Diagnostic PCR protocols can be found at https://www.who.int/health-topics/coronavirus/laboratory-diagnostics-for-novel-co ronavirus."],"journal":"J Infect Dev Ctries","authors":["Ralph, Robyn","Lew, Jocelyne","Zeng, Tiansheng","Francis, Magie","Xue, Bei","Roux, Melissa","Toloue Ostadgavahi, Ali","Rubino, Salvatore","Dawe, Nicholas J","Al-Ahdal, Mohammed N","Kelvin, David J","Richardson, Christopher D","Kindrachuk, Jason","Falzarano, Darryl","Kelvin, Alyson Anne"],"date":"2020-02-24T11:00:00Z","year":2020,"_id":"32088679","week":"20209|Feb 24 - Mar 01","doi":"10.3855/jidc.12425","keywords":["2019-nCoV","Wuhan","coronavirus","human-to-human transmission","vaccine readiness"],"source":"PubMed","locations":["Canada","Germany","Vietnam","United States","South Korea","Japan","Wuhan","China","France","Thailand"],"countries":["France","United States","Japan","Thailand","Canada","Korea, Republic of","Germany","China","Viet Nam"],"countries_codes":["FRA|France","USA|United States","JPN|Japan","THA|Thailand","CAN|Canada","KOR|Korea, Republic of","DEU|Germany","CHN|China","VNM|Viet Nam"],"topics":["Treatment"],"weight":1,"_version_":1661359647405113344,"score":63.990932},{"pmid":31987001,"title":"Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan.","text":["Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan.","A mysterious outbreak of atypical pneumonia in late 2019 was traced to a seafood wholesale market in Wuhan of China. Within a few weeks, a novel coronavirus tentatively named as 2019 novel coronavirus (2019-nCoV) was announced by the World Health Organization. We performed bioinformatics analysis on a virus genome from a patient with 2019-nCoV infection and compared it with other related coronavirus genomes. Overall, the genome of 2019-nCoV has 89% nucleotide identity with bat SARS-like-CoVZXC21 and 82% with that of human SARS-CoV. The phylogenetic trees of their orf1a/b, Spike, Envelope, Membrane and Nucleoprotein also clustered closely with those of the bat, civet and human SARS coronaviruses. However, the external subdomain of Spike's receptor binding domain of 2019-nCoV shares only 40% amino acid identity with other SARS-related coronaviruses. Remarkably, its orf3b encodes a completely novel short protein. Furthermore, its new orf8 likely encodes a secreted protein with an alpha-helix, following with a beta-sheet(s) containing six strands. Learning from the roles of civet in SARS and camel in MERS, hunting for the animal source of 2019-nCoV and its more ancestral virus would be important for understanding the origin and evolution of this novel lineage B betacoronavirus. These findings provide the basis for starting further studies on the pathogenesis, and optimizing the design of diagnostic, antiviral and vaccination strategies for this emerging infection.","Emerg Microbes Infect","Chan, Jasper Fuk-Woo","Kok, Kin-Hang","Zhu, Zheng","Chu, Hin","To, Kelvin Kai-Wang","Yuan, Shuofeng","Yuen, Kwok-Yung","31987001"],"abstract":["A mysterious outbreak of atypical pneumonia in late 2019 was traced to a seafood wholesale market in Wuhan of China. Within a few weeks, a novel coronavirus tentatively named as 2019 novel coronavirus (2019-nCoV) was announced by the World Health Organization. We performed bioinformatics analysis on a virus genome from a patient with 2019-nCoV infection and compared it with other related coronavirus genomes. Overall, the genome of 2019-nCoV has 89% nucleotide identity with bat SARS-like-CoVZXC21 and 82% with that of human SARS-CoV. The phylogenetic trees of their orf1a/b, Spike, Envelope, Membrane and Nucleoprotein also clustered closely with those of the bat, civet and human SARS coronaviruses. However, the external subdomain of Spike's receptor binding domain of 2019-nCoV shares only 40% amino acid identity with other SARS-related coronaviruses. Remarkably, its orf3b encodes a completely novel short protein. Furthermore, its new orf8 likely encodes a secreted protein with an alpha-helix, following with a beta-sheet(s) containing six strands. Learning from the roles of civet in SARS and camel in MERS, hunting for the animal source of 2019-nCoV and its more ancestral virus would be important for understanding the origin and evolution of this novel lineage B betacoronavirus. These findings provide the basis for starting further studies on the pathogenesis, and optimizing the design of diagnostic, antiviral and vaccination strategies for this emerging infection."],"journal":"Emerg Microbes Infect","authors":["Chan, Jasper Fuk-Woo","Kok, Kin-Hang","Zhu, Zheng","Chu, Hin","To, Kelvin Kai-Wang","Yuan, Shuofeng","Yuen, Kwok-Yung"],"date":"2020-01-29T11:00:00Z","year":2020,"_id":"31987001","week":"20205|Jan 27 - Feb 02","doi":"10.1080/22221751.2020.1719902","keywords":["Coronavirus","SARS","Wuhan","bioinformatics","emerging","genome","respiratory","virus"],"link_erratum_in":"32133926","source":"PubMed","locations":["MERS","Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism"],"weight":1,"_version_":1661359647088443392,"score":58.993378},{"pmid":32169119,"title":"The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status.","text":["The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status.","An acute respiratory disease, caused by a novel coronavirus (SARS-CoV-2, previously known as 2019-nCoV), the coronavirus disease 2019 (COVID-19) has spread throughout China and received worldwide attention. On 30 January 2020, World Health Organization (WHO) officially declared the COVID-19 epidemic as a public health emergency of international concern. The emergence of SARS-CoV-2, since the severe acute respiratory syndrome coronavirus (SARS-CoV) in 2002 and Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012, marked the third introduction of a highly pathogenic and large-scale epidemic coronavirus into the human population in the twenty-first century. As of 1 March 2020, a total of 87,137 confirmed cases globally, 79,968 confirmed in China and 7169 outside of China, with 2977 deaths (3.4%) had been reported by WHO. Meanwhile, several independent research groups have identified that SARS-CoV-2 belongs to beta-coronavirus, with highly identical genome to bat coronavirus, pointing to bat as the natural host. The novel coronavirus uses the same receptor, angiotensin-converting enzyme 2 (ACE2) as that for SARS-CoV, and mainly spreads through the respiratory tract. Importantly, increasingly evidence showed sustained human-to-human transmission, along with many exported cases across the globe. The clinical symptoms of COVID-19 patients include fever, cough, fatigue and a small population of patients appeared gastrointestinal infection symptoms. The elderly and people with underlying diseases are susceptible to infection and prone to serious outcomes, which may be associated with acute respiratory distress syndrome (ARDS) and cytokine storm. Currently, there are few specific antiviral strategies, but several potent candidates of antivirals and repurposed drugs are under urgent investigation. In this review, we summarized the latest research progress of the epidemiology, pathogenesis, and clinical characteristics of COVID-19, and discussed the current treatment and scientific advancements to combat the epidemic novel coronavirus.","Mil Med Res","Guo, Yan-Rong","Cao, Qing-Dong","Hong, Zhong-Si","Tan, Yuan-Yang","Chen, Shou-Deng","Jin, Hong-Jun","Tan, Kai-Sen","Wang, De-Yun","Yan, Yan","32169119"],"abstract":["An acute respiratory disease, caused by a novel coronavirus (SARS-CoV-2, previously known as 2019-nCoV), the coronavirus disease 2019 (COVID-19) has spread throughout China and received worldwide attention. On 30 January 2020, World Health Organization (WHO) officially declared the COVID-19 epidemic as a public health emergency of international concern. The emergence of SARS-CoV-2, since the severe acute respiratory syndrome coronavirus (SARS-CoV) in 2002 and Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012, marked the third introduction of a highly pathogenic and large-scale epidemic coronavirus into the human population in the twenty-first century. As of 1 March 2020, a total of 87,137 confirmed cases globally, 79,968 confirmed in China and 7169 outside of China, with 2977 deaths (3.4%) had been reported by WHO. Meanwhile, several independent research groups have identified that SARS-CoV-2 belongs to beta-coronavirus, with highly identical genome to bat coronavirus, pointing to bat as the natural host. The novel coronavirus uses the same receptor, angiotensin-converting enzyme 2 (ACE2) as that for SARS-CoV, and mainly spreads through the respiratory tract. Importantly, increasingly evidence showed sustained human-to-human transmission, along with many exported cases across the globe. The clinical symptoms of COVID-19 patients include fever, cough, fatigue and a small population of patients appeared gastrointestinal infection symptoms. The elderly and people with underlying diseases are susceptible to infection and prone to serious outcomes, which may be associated with acute respiratory distress syndrome (ARDS) and cytokine storm. Currently, there are few specific antiviral strategies, but several potent candidates of antivirals and repurposed drugs are under urgent investigation. In this review, we summarized the latest research progress of the epidemiology, pathogenesis, and clinical characteristics of COVID-19, and discussed the current treatment and scientific advancements to combat the epidemic novel coronavirus."],"journal":"Mil Med Res","authors":["Guo, Yan-Rong","Cao, Qing-Dong","Hong, Zhong-Si","Tan, Yuan-Yang","Chen, Shou-Deng","Jin, Hong-Jun","Tan, Kai-Sen","Wang, De-Yun","Yan, Yan"],"date":"2020-03-15T11:00:00Z","year":2020,"_id":"32169119","week":"202011|Mar 09 - Mar 15","doi":"10.1186/s40779-020-00240-0","keywords":["Clinical characteristics","Coronavirus disease 2019 (COVID-19)","Origin","SARS-CoV-2","Therapy","Transmission"],"source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Diagnosis","Treatment"],"weight":1,"_version_":1661359647907381248,"score":58.635017},{"pmid":32120913,"title":"Epidemiological Identification of A Novel Pathogen in Real Time: Analysis of the Atypical Pneumonia Outbreak in Wuhan, China, 2019-2020.","text":["Epidemiological Identification of A Novel Pathogen in Real Time: Analysis of the Atypical Pneumonia Outbreak in Wuhan, China, 2019-2020.","Virological tests have now shown conclusively that a novel coronavirus is causing the 2019-2020 atypical pneumonia outbreak in Wuhan, China. We demonstrate that non-virological descriptive characteristics could have determined that the outbreak is caused by a novel pathogen in advance of virological testing. Characteristics of the ongoing outbreak were collected in real time from two medical social media sites. These were compared against characteristics of eleven pathogens that have previously caused cases of atypical pneumonia. The probability that the current outbreak is due to \"Disease X\" (i.e., previously unknown etiology) as opposed to one of the known pathogens was inferred, and this estimate was updated as the outbreak continued. The probability (expressed as a percentage) that Disease X is driving the outbreak was assessed as over 29% on 31 December 2019, one week before virus identification. After some specific pathogens were ruled out by laboratory tests on 5 January 2020, the inferred probability of Disease X was over 49%. We showed quantitatively that the emerging outbreak of atypical pneumonia cases is consistent with causation by a novel pathogen. The proposed approach, which uses only routinely observed non-virological data, can aid ongoing risk assessments in advance of virological test results becoming available.","J Clin Med","Jung, Sung-Mok","Kinoshita, Ryo","Thompson, Robin N","Linton, Natalie M","Yang, Yichi","Akhmetzhanov, Andrei R","Nishiura, Hiroshi","32120913"],"abstract":["Virological tests have now shown conclusively that a novel coronavirus is causing the 2019-2020 atypical pneumonia outbreak in Wuhan, China. We demonstrate that non-virological descriptive characteristics could have determined that the outbreak is caused by a novel pathogen in advance of virological testing. Characteristics of the ongoing outbreak were collected in real time from two medical social media sites. These were compared against characteristics of eleven pathogens that have previously caused cases of atypical pneumonia. The probability that the current outbreak is due to \"Disease X\" (i.e., previously unknown etiology) as opposed to one of the known pathogens was inferred, and this estimate was updated as the outbreak continued. The probability (expressed as a percentage) that Disease X is driving the outbreak was assessed as over 29% on 31 December 2019, one week before virus identification. After some specific pathogens were ruled out by laboratory tests on 5 January 2020, the inferred probability of Disease X was over 49%. We showed quantitatively that the emerging outbreak of atypical pneumonia cases is consistent with causation by a novel pathogen. The proposed approach, which uses only routinely observed non-virological data, can aid ongoing risk assessments in advance of virological test results becoming available."],"journal":"J Clin Med","authors":["Jung, Sung-Mok","Kinoshita, Ryo","Thompson, Robin N","Linton, Natalie M","Yang, Yichi","Akhmetzhanov, Andrei R","Nishiura, Hiroshi"],"date":"2020-03-04T11:00:00Z","year":2020,"_id":"32120913","week":"202010|Mar 02 - Mar 08","doi":"10.3390/jcm9030637","keywords":["Bayes' theorem","causation","diagnosis","epidemic","prediction","statistical model"],"source":"PubMed","locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Epidemic Forecasting"],"weight":1,"_version_":1661359647623217152,"score":57.852707}]}